- Home
- HLVX vs THTX Comparison
HLVX vs THTX Comparison
Compare HLVX & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- THTX
- Stock Information
- Founded
- HLVX 2020
- THTX 1993
- Country
- HLVX United States
- THTX Canada
- Employees
- HLVX N/A
- THTX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- THTX Health Care
- Exchange
- HLVX Nasdaq
- THTX Nasdaq
- Market Cap
- HLVX 92.6M
- THTX 93.3M
- IPO Year
- HLVX 2022
- THTX N/A
- Fundamental
- Price
- HLVX $1.83
- THTX $1.85
- Analyst Decision
- HLVX Hold
- THTX Hold
- Analyst Count
- HLVX 5
- THTX 1
- Target Price
- HLVX $2.33
- THTX N/A
- AVG Volume (30 Days)
- HLVX 176.5K
- THTX 89.0K
- Earning Date
- HLVX 03-19-2025
- THTX 04-09-2025
- Dividend Yield
- HLVX N/A
- THTX N/A
- EPS Growth
- HLVX N/A
- THTX N/A
- EPS
- HLVX N/A
- THTX N/A
- Revenue
- HLVX N/A
- THTX $84,316,000.00
- Revenue This Year
- HLVX N/A
- THTX $5.78
- Revenue Next Year
- HLVX N/A
- THTX $2.47
- P/E Ratio
- HLVX N/A
- THTX N/A
- Revenue Growth
- HLVX N/A
- THTX 5.75
- 52 Week Low
- HLVX $1.55
- THTX $1.08
- 52 Week High
- HLVX $20.22
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- HLVX 43.02
- THTX 58.80
- Support Level
- HLVX $1.67
- THTX $1.56
- Resistance Level
- HLVX $1.99
- THTX $2.06
- Average True Range (ATR)
- HLVX 0.08
- THTX 0.14
- MACD
- HLVX -0.00
- THTX 0.04
- Stochastic Oscillator
- HLVX 48.48
- THTX 68.84
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.